



Robert Greene Sterne  
Jorge A. Goldstein  
David K.S. Cornwell  
Robert W. Esmond  
Tracy-Gene G. Durkin  
Michele A. Cimbala  
Michael B. Ray  
Robert E. Sokohl  
Eric K. Steffe  
Michael Q. Lee  
Steven R. Ludwig  
John M. Covert  
Linda E. Horner  
Robert C. Millionig  
Donald J. Featherstone  
Timothy J. Shea, Jr  
Michael V. Messinger  
Judith U. Kim

Patrick E. Garrett  
Jeffrey T. Helvey  
Heidi L. Kraus  
Eldora L. Ellison  
Thomas C. Fiala  
Donald R. Banowitz  
Peter A. Jackman  
Jeffrey S. Weaver  
Brian J. Del Buono  
Vincent L. Capuano  
Virgil Lee Beaton  
Theodore A. Wood  
Elizabeth J. Haanes  
Joseph S. Ostroff  
Frank R. Cottingham  
Rae Lynn P. Guest  
Daniel A. Klein  
Jason D. Eisenberg

Michael D. Specht  
Tracy L. Muller  
Jon E. Wright  
LuAnne M. DeSantis  
Ann E. Summerfield  
Helene C. Carlson  
Cynthia M. Bouchez  
Timothy A. Doyle  
Gabry L. Longworth  
Lori A. Gordon  
Ted J. Ebersole  
Laura A. Vogel  
Bryan S. Wade  
Bashir M.S. Ali  
Shannon A. Carroll  
Matthew E. Kelley  
Michelle K. Holoubek  
Marsha A. Rose\*

W. Blake Coblenz  
James J. Pohl\*  
John T. Haran\*  
Mark W. Rygiel

**Registered Patent Agents\***  
Karen R. Markowicz  
Matthew J. Dowd  
Katrina Yujian Pei Quach  
Bryan L. Skelton  
Robert A. Schwartzman  
Teresa A. Colella  
Victoria S. Rutherford  
Simon J. Elliott  
Julie A. Heider  
Mita Mukherjee  
Scott M. Woodhouse  
Christopher J. Walsh

Liliana Di Nola-Baron  
Peter A. Socarras  
Jeffrey Mills  
Danielle L. Letting  
Lori Brandes

**Of Counsel**  
Edward J. Kessler  
Kenneth C. Bass III  
Marvin C. Guthrie

\*Admitted only in Maryland  
\*Admitted only in Virginia  
•Practice Limited to  
Federal Agencies

September 12, 2006

**WRITER'S DIRECT NUMBER:**  
(202) 772-8822  
**INTERNET ADDRESS:**  
SCARROLL@SKGF.COM

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**Attn: Mail Stop Amendment**

Re: U.S. Utility Patent Application  
Application No. 10/587,714; (*National Phase of PCT/US2005/002535*)  
Int'l. Filing Date: January 28, 2005  
For: **Treatment of Conditions Involving Dopaminergic Neuronal  
Degeneration Using Nogo Receptor Antagonists**  
Inventors: Relton *et al.*  
Our Ref: 2159.0450001/EJH/SAC

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Information Disclosure Statement Under 37 C.F.R. § 1.97(b);
2. Listing of the cited documents on Form PTO/SB/08A (2 sheets);
3. A copy of sixteen (16) cited documents on Form PTO/SB/08A;
4. A listing of the cited documents on Form PTO/SB/08B (3 sheets);
5. A copy of twenty-five (25) cited documents on Form PTO/SB/08B;
6. First Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97(b);
7. A listing of the cited documents on Form PTO/SB/08A (1 sheet);
8. A listing of the cited documents on Form PTO/SB/08B (2 sheets);
9. A copy of the eleven (11) cited documents on Form PTO/SB/08B;
10. Second Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97(b);

Commissioner for Patents  
September 12, 2006  
Page 2


11. A listing of the cited documents on Form PTO/SB/08A (1 sheet);
12. A listing of the cited documents on Form PTO/SB/08B (1 sheet);
13. A copy of the three (3) cited documents on Form PTO/SB/08B; and
14. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

*for*  #42,613  
Shannon A. Carroll, Ph.D.  
Attorney for Applicants  
Registration No. 58,240

SAC/rjv  
Enclosures

581706\_1.DOC



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Relton *et al.*Appl. No.: 10/587,714 (*National Phase of  
PCT/US2005/002535*)

Intl Filing Date: January 28, 2005

For: **Treatment of Conditions Involving  
Dopaminergic Neuronal  
Degeneration Using Nogo Receptor  
Antagonists**

Confirmation No.: 2306

Art Unit: *To be assigned*Examiner: *To be assigned*

Atty. Docket: 2159.0450001/EJH/SAC

**Information Disclosure Statement Under 37 C.F.R. § 1.97(b)*****Mail Stop Amendment***Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Forms PTO/SB/08A and PTO/SB/08B are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Copies of documents **FP1-FP16** and **NPL1-NPL25** are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and patent application publications, documents **US1-US22**, cited on the attached Form PTO/SB/08A are not submitted.

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative submits the following discussion of the relevance of the non-English language document **FP10** cited on Form PTO/SB/08A:

Document **FP10**, WO 93/01288 A1, is in a foreign language. The relevance of document **FP10** may be found in the English language abstract included on the face page of said document.

- 2 -

Relton *et al.*  
Appl. No. 10/587,714  
(National Phase of PCT/US2005/002535)

The Examiner's attention is directed to the following U.S. Patent Applications and PCT Patent Applications, which are directed to related technical subject matter:

U.S. Patent Application No. 09/758,140 inventor Strittmatter S.M., filed January 12, 2001; published as US 2002/0012965 A1, cited herein as document **US19**;

U.S. Patent Application No. 09/972,599, inventor Strittmatter S.M., filed October 6, 2001; published as US2002/0077295 A1, cited herein as document **US20**;

U.S. Patent Application No. 09/972,546, inventors Strittmatter *et al.*, filed October 6, 2001; published as US2003/0124704 A1, cited herein as document **US21**;

U.S. Patent Application No. 10/735,256, inventors Strittmatter *et al.*, filed December 12, 2003; published as US2005/0048520 A1, cited herein as document **US22**;

PCT Patent Application No. PCT/US01/01041, applicant Yale University, filed January 12, 2001, published as WO 01/51520 A2, cited herein as document **FP11**;

PCT Patent Application No. PCT/US01/31488, applicants Yale University and Biogen, Inc., filed October 06, 2001, published as WO 02/29059 A2, cited herein as document **FP12**;

PCT Patent Application No. PCT/US02/32007, applicant Yale University, filed October 04, 2002, published as WO 03/031462 A2, cited herein as document **FP13**;

PCT Patent Application No. PCT/US2003/025004, applicant Yale University and Biogen, Inc., filed August 07, 2003, published as WO 04/014311 A2, cited herein as document **FP14**;

PCT Patent Application No. PCT/US2004/011728, applicants and inventors Strittmatter *et al.*, filed April 16, 2004, published as WO 04/093893 A2, cited herein as document **FP15**; and

Atty. Dkt. No. 2159.0450001/EJH/SAC

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SLW/

- 3 -

Relton *et al.*  
Appl. No. 10/587,714  
(National Phase of PCT/US2005/002535)

PCT Patent Application No. PCT/US04/002702, applicants and inventors Lee *et al.*, filed January 30, 2004, published as WO 05/016955 A2, cited herein as document **FP16**.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed within three months of the date of filing. No statement or fee is required.

It is respectfully requested that the Examiner initial and return copies of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

Atty. Dkt. No. 2159.0450001/EJH/SAC

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SLW/


- 4 -

Relton *et al.*  
Appl. No. 10/587,714  
(National Phase of PCT/US2005/002535)

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

 #42,613  
Shannon A. Carroll, Ph.D.  
Attorney for Applicants  
Registration No. 58,240


Date:

Sept. 14, 2006  
1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600

580268\_1.DOC

Atty. Dkt. No. 2159.0450001/EJH/SAC

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SLW/



10587714 - GAU: 1646

Equivalent of Form PTO/SB/08A (08-03)

Approved for use through 07/31/2006.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/587,714 (Nat'l. Phase of PCT/US2005/002535)
				Intl. Filing Date	January 28, 2005
				First Named Inventor	Relton, Jane K.
				Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	1	of	2	Attorney Docket Number	2159.0450001/EJH/SAC

U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number-Kind Code <sup>2</sup> (if Known)		
	US1	3,817,837	06/18/1974	Rubenstein <i>et al.</i>
	US2	3,850,752	11/26/1974	Schuurs <i>et al.</i>
	US3	3,939,350	02/17/1976	Kronick <i>et al.</i>
	US4	3,996,345	12/07/1976	Ullman <i>et al.</i>
	US5	4,275,149	06/23/1981	Litman <i>et al.</i>
	US6	4,277,437	07/07/1981	Maggio
	US7	4,366,241	12/28/1982	Tom <i>et al.</i>
	US8	4,399,216	08/16/1983	Axel <i>et al.</i>
	US9	4,510,245	04/09/1985	Cousens <i>et al.</i>
	US10	4,634,665	01/06/1987	Axel <i>et al.</i>
	US11	4,816,567	03/28/1989	Cabilly <i>et al.</i>
	US12	4,968,615	11/06/1990	Koszinowski <i>et al.</i>
	US13	5,168,062	12/01/1992	Stinski
	US14	5,179,017	01/12/1993	Axel <i>et al.</i>
	US15	5,223,409	06/29/1993	Ladner <i>et al.</i>
	US16	5,877,293	03/02/1999	Adair <i>et al.</i>
	US17	5,886,152	03/23/1999	Nakatani <i>et al.</i>
	US18	6,054,297	04/25/2000	Carter <i>et al.</i>
	US19	US2002/0012965 A1	01/31/2002	Strittmatter
	US20	US2002/0077295 A1	06/20/2002	Strittmatter

FOREIGN PATENT DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>2</sup> (if known)		
	FP1	EP 0 216 846 B1	01/10/1990	CellTech Limited
	FP2	EP 0 256 055 B1	08/28/1991	CellTech Limited
	FP3	EP 0 323 997 B1	04/21/1993	CellTech Limited
	FP4	WO 91/17271 A1	11/14/1991	Affymax Technologies N.V.
	FP5	WO 92/01047 A1	01/23/1992	Cambridge Antibody Technology Limited
	FP6	WO 92/09690 A2	06/11/1992	Genentech, Inc.
	FP7	WO 92/15679 A1	09/17/1992	Protein Engineering Corporation
	FP8	WO 92/18619 A1	10/29/1992	The Scripps Research Institute
	FP9	WO 92/20791 A1	11/26/1992	Cambridge Antibody Technology Limited
	FP10	WO 93/01288 A1	01/21/1993	Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts
	FP11	WO 01/51520 A2	07/19/2001	Yale University
	FP12	WO 02/29059 A2	04/11/2002	Yale University; Biogen, Inc.

Examiner Signature	/Sandra Wegert/	Date Considered	09/14/2009
--------------------	-----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \* See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \* Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \* Applicant is to place a check mark here if English language Translation is attached.


This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SLW/

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SLW/





PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	10/587,714 (Natl. Phase of PCT/US2005/002535)
				Intl. Filing Date	January 28, 2005
				First Named Inventor	Relton, Jane K.
				Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	1	of	3	Attorney Docket Number	2159.0450001/EJH/SAC

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>	
	NPL1	Basso, D.M., <i>et al.</i> , "MASCIS Evaluation of Open Field Locomotor Scores: Effects of Experience and Teamwork on Reliability," <i>J. Neurotrauma</i> 13:343-359, Mary Ann Liebert, Inc. (1996)		
	NPL2	Brittis, P.A. and Flanagan, J.G., "Nogo Domains and a Nogo Receptor: Implications for Axon Regeneration," <i>Neuron</i> 30:11-14, Cell Press (April 2001)		
	NPL3	Chen, M.S., <i>et al.</i> , "Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1," <i>Nature</i> 403:434-439, Macmillan Magazines Ltd. (2000)		
	NPL4	Domeniconi, M., <i>et al.</i> , "Myelin-Associated Glycoprotein Interacts with the Nogo66 Receptor to Inhibit Neurite Outgrowth," <i>Neuron</i> 35:283-290, Cell Press (July 2002)		
	NPL5	Fournier, A.E., <i>et al.</i> , "Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration," <i>Nature</i> 409:341-346, Macmillan Magazines Ltd. (January 2001)		
	NPL6	Fournier, A.E., <i>et al.</i> , "Truncated Soluble Nogo Receptor Binds Nogo-66 and Blocks Inhibition of Axon Growth by Myelin," <i>J. Neurosci.</i> 22:8876-8883, Society of Neuroscience with the assistance of Stanford University's HighWire Press™ (October 2002)		
	NPL7	Grandpré, T., <i>et al.</i> , "Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein," <i>Nature</i> 403:439-444, Macmillan Magazines Ltd. (2000)		
	NPL8	Grandpré, T., <i>et al.</i> , "Nogo-66 receptor antagonist peptide promotes axonal regeneration," <i>Nature</i> 417:547-551, Nature Publishing Group (May 2002)		
	NPL9	Grimpe, B., <i>et al.</i> , "The Critical Role of Basement Membrane-Independent Laminin γ1 Chain during Axon Regeneration in the CNS," <i>J. Neurosci.</i> 22:3144-3160, Society for Neuroscience with the assistance of Stanford University's HighWire Press™ (April 2002)		
	NPL10	Jones, L.L., <i>et al.</i> , "NG2 Is a Major Chondroitin Sulfate Proteoglycan Produced after Spinal Cord Injury and Is Expressed by Macrophages and Oligodendrocyte Progenitors," <i>J. Neurosci.</i> 22:2792-2803, Society for Neuroscience with the assistance of Stanford University's HighWire Press™ (April 2002)		
Examiner Signature	/Sandra Wegert/		Date Considered	09/14/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SLW/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/587,714 (Natl. Phase of PCT/US2005/002535)
				Intl. Filing Date	January 28, 2005
				First Named Inventor	Relton, Jane K.
				Art Unit	To be assigned
Examiner Name	To be assigned				
Sheet	2	of	3	Attorney Docket Number	2159.0450001/EJH/SAC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>
	NPL11	Li, M., <i>et al.</i> , "Functional Role and Therapeutic Implications of Neuronal Caspase-1 and -3 in a Mouse Model of Traumatic Spinal Cord Injury," <i>Neurosci.</i> 99:333-342, Elsevier Science Ltd. (2000)	
	NPL12	Li, S. and Strittmatter, S.M., "Delayed Systemic Nogo-66 Receptor Antagonist Promotes Recovery from Spinal Cord Injury," <i>J. Neurosci.</i> 23:4219-4227, Society for Neuroscience with the assistance of Stanford University's HighWire Press™ (May 2003)	
	NPL13	Liu, B.P., <i>et al.</i> , "Myelin-Associated Glycoprotein as a Functional Ligand for the Nogo-66 Receptor," <i>Science</i> 297:1190-1193, American Association for the Advancement of Science (published online June 27, 2002)	
	NPL14	Liu, Y., <i>et al.</i> , "Transplants of Fibroblasts Genetically Modified to Express BDNF Promote Regeneration of Adult Rat Rubrospinal Axons and Recovery of Forelimb Function," <i>J. Neurosci.</i> 19:4370-4387, Society for Neuroscience with the assistance of Stanford University's HighWire Press™ (1999)	
	NPL15	McKerracher, L., <i>et al.</i> , "Identification of Myelin-Associated Glycoprotein as a Major Myelin-Derived Inhibitor of Neurite Growth," <i>Neuron</i> 13:805-811, Cell Press (1994)	
	NPL16	Metz, G.A.S., <i>et al.</i> , "Efficient testing of motor function in spinal cord injured rats," <i>Brain Res.</i> 883:165-177, Elsevier Science B.V. (2000)	
	NPL17	Mikol, D.D. and Stefansson, K., "A Phosphatidylinositol-linked Peanut Agglutinin-binding Glycoprotein in Central Nervous System Myelin and on Oligodendrocytes," <i>J. Cell. Biol.</i> 106:1273-1279, The Rockefeller University Press (1988)	
	NPL18	Mukhopadhyay, G., <i>et al.</i> , "A Novel Role for Myelin-Associated Glycoprotein as an Inhibitor of Axonal Regeneration," <i>Neuron</i> 13:757-767, Cell Press (1994)	
	NPL19	Noël, D., <i>et al.</i> , "High <i>In Vivo</i> Production of a Model Monoclonal Antibody on Adenoviral Gene Transfer," <i>Human Gene Therapy</i> 13:1483-1493, Mary Ann Liebert, Inc. (August 2002)	
	NPL20	Ramon-Cueto, A., <i>et al.</i> , "Functional Recovery of Paraplegic Rats and Motor Axon Regeneration in Their Spinal Cords by Olfactory Ensheathing Glia," <i>Neuron</i> 25:425-435, Cell Press (2000)	

Examiner Signature	/Sandra Wegert/	Date Considered	09/14/2009
--------------------	-----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SLW/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	10/587,714 (Natl. Phase of PCT/US2005/002535)
				Intl. Filing Date	January 28, 2005
				First Named Inventor	Relton, Jane K.
				Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	3	of	3	Attorney Docket Number	2159.0450001/EJH/SAC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>
	NPL21	Rutishauser, U. and Jessell, T.M., "Cell Adhesion Molecules in Vertebrate Neural Development," <i>Physiol. Rev.</i> 68:819-857, the American Physiological Society (1988)	
	NPL22	Wang, K.C., <i>et al.</i> , "Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth," <i>Nature</i> 417:941-944, Nature Publishing Group (June 2002)	
	NPL23	Wang, X., <i>et al.</i> , "Localization of Nogo-A and Nogo-66 Receptor Proteins at Sites of Axon-Myelin and Synaptic Contact," <i>J. Neurosci.</i> 22:5505-5515, Society for Neuroscience with the assistance of Stanford University's HighWire Press™ (July 2002)	
	NPL24	Wang, H.-Y., <i>et al.</i> , "Amyloid Peptide A $\beta$ <sub>1-42</sub> Binds Selectively and with Picomolar Affinity to $\alpha$ 7 Nicotinic Acetylcholine Receptors," <i>J. Neurochem.</i> 75:1155-1161, Lippincott Williams & Wilkins, Inc. (2000)	
	NPL25	Weidner, N., <i>et al.</i> , "Spontaneous corticospinal axonal plasticity and functional recovery after adult central nervous system injury," <i>Proc. Natl. Acad. Sci. USA</i> 98:3513-3518, The National Academy of Sciences (March 2001)	

526740\_1.DOC

Examiner Signature	/Sandra Wegert/	Date Considered	09/14/2009
-----------------------	-----------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SLW/



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Relton *et al.*Appl. No.: 10/587,714 (*National Phase of  
PCT/US2005/002535*)

Intl. Filing Date: January 28, 2005

**For: Treatment of Conditions Involving  
Dopaminergic Neuronal  
Degeneration Using Nogo Receptor  
Antagonists**

Confirmation No.: 2306

Art Unit: *To be assigned*Examiner: *To be assigned*

Atty. Docket: 2159.0450001/EJH/SAC

**First Supplemental Information Disclosure Statement  
Under 37 C.F.R. § 1.97(b)*****Mail Stop Amendment***Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Forms PTO/SB/08A and PTO/SB/08B are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this First Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Information Disclosure Statement filed herewith in connection with the above-captioned application.

Copies of documents **NPL26-NPL36** are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and patent application publications, documents **US23-US28**, cited on the attached Form PTO/SB/08A are not submitted.

The Examiner's attention is directed to the following U.S. Patent Application, which is directed to related technical subject matter:

- 2 -

Relton *et al.*  
Appl. No. 10/587,714  
(National Phase of PCT/US2005/002535)

U.S. Patent Application No. 11/055,163, inventors Lee *et al.*, filed February 10, 2005; published as US2005/0271655 A1, cited herein as document **US28**;

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed within three months of the date of filing. No statement or fee is required.

Atty. Dkt. No. 2159.0450001/EJH/SAC

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SLW/

- 3 -

Relton *et al.*  
Appl. No. 10/587,714  
(National Phase of PCT/US2005/002535)

It is respectfully requested that the Examiner initial and return copies of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

*for Shannon A. Carroll, Ph.D.* #42613  
Shannon A. Carroll, Ph.D.  
Attorney for Applicants  
Registration No. 58,240


Date: Sept 12, 2006  
1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600

580282\_1.DOC

Atty. Dkt. No. 2159.0450001/EJH/SAC

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SLW/

10587714 - GAU: 1646



10587714 - GAU: 1646

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/587,714 (National Phase of PCT/US2005/002535)
				I.A. Filing Date	January 28, 2005
				First Named Inventor	Relton, Jane K.
				Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	1	of	2	Attorney Docket Number	2159.0450001/EJH/SAC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	NPL26	Fournier, A.E., <i>et al.</i> , "Characterization of the neuronal receptor mediating Nogo-66 inhibition of axonal regeneration," <i>J. Neurochem.</i> 78 (Suppl. 1):105, Blackwell Publishing, Abstract No. S08-01 (September 2001)	
	NPL27	Fournier, A.E., <i>et al.</i> , "Nogo Receptor Domain Analysis," <i>Society for Neuroscience Abstracts</i> 27:670, Society for Neuroscience, Abstract No. 258.3, presented at the <i>Society for Neuroscience's 31st Annual Meeting</i> , San Diego, CA (November 12, 2001)	
	NPL28	GrandPre, T.J., <i>et al.</i> , "Functional Analysis of Nogo-66 and Nogo Receptor Domains," <i>Society for Neuroscience Abstracts</i> 27:670, Society for Neuroscience, Abstract No. 258.4, presented at the <i>Society for Neuroscience's 31st Annual Meeting</i> , San Diego, CA (November 12, 2001)	
	NPL29	International Search Report for International Application No. PCT/US2005/002535, European Patent Office, Netherlands, mailed October 24, 2005	
	NPL30	International Search Report for International Application No. PCT/US05/35719, ISA/US, Alexandria, VA, mailed April 13, 2006	
	NPL31	International Search Report for International Application No. PCT/US2004/02702, ISA/US, Alexandria, VA, mailed April 20, 2006	
	NPL32	Li, M., <i>et al.</i> , "Effect of soluble Nogo receptor treatment on functional and histological outcome after spinal cord injury in the rat," <i>Biosis Database</i> , Accession No. PREV200400194121, Abstract No. 80.22, <i>Presented at the 33rd Annual Meeting of the Society of Neuroscience</i> , New Orleans, LA (November 8-12, 2003)	
	NPL33	Li, W., <i>et al.</i> , "A Neutralizing Anti-Nogo66 Receptor Monoclonal Antibody Reverses Inhibition of Neurite Outgrowth by Central Nervous System Myelin," <i>J. Biol. Chem.</i> 42:43780-43788, The American Society for Biochemistry and Molecular Biology, Inc. (October 2004)	
	NPL34	Li, W., <i>et al.</i> , "Neutralization of NGR1 May Be Sufficient to Promote Rat DRG Neurite Outgrowth in the Presence of CNS Myeline," <i>SFN 2003 Abstract Viewer &amp; Itinerary Planner</i> , Program No. 678.3, <i>Presented at the 33rd Annual Meeting of the Society of Neuroscience</i> , New Orleans, LA (November 8-12, 2003)	

Examiner Signature	/Sandra Wegert/	Date Considered	09/14/2009
--------------------	-----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SLW/



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

[illegible]

Examiner Signature	/Sandra Wegert/	Date Considered	09/14/2009
-----------------------	-----------------	--------------------	------------

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SLW/



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Relton *et al.*Appl. No.: 10/587,714 (*National Phase of PCT/US2005/002535*)

Intl. Filing Date: January 28, 2005

For: **Treatment of Conditions Involving  
Dopaminergic Neuronal  
Degeneration Using Nogo Receptor  
Antagonists**

Confirmation No.: 2306

Art Unit: *To be assigned*Examiner: *To be assigned*

Atty. Docket: 2159.0450001/EJH/SAC

**Second Supplemental Information Disclosure Statement  
Under 37 C.F.R. § 1.97(b)**

*Mail Stop Amendment*

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Forms, PTO/SB/08A and PTO/SB/08B, are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Second Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' First Supplemental Information Disclosure Statement filed on July 14, 2006 in connection with the above-captioned application.

Copies of documents **NPL37** to **NPL39** are provided. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and patent application publications, documents **US29-US32**, cited on the attached Form PTO/SB/08A are not submitted. In addition, copies of documents **NPL40** and **NPL41**, cited on the attached Form PTO/SB/08B are not provided in accordance with the U.S. Patent and Trademark Office

- 2 -

Relton *et al.*  
Appl. No. 10/587,714  
(National Phase of PCT/US2005/002535)

OG notice of October 19, 2004, which states: "the requirement in 37 C.F.R. § 1.98(a)(2)(iii) for a legible copy of the specification, including the claims, and drawings of each cited pending U.S. patent application (or portion of the application which caused it to be listed) is sua sponte waived where the cited pending application is stored in the USPTO's IFW system."

The Examiner's attention is directed to the following U.S. Patent Applications, which are directed to related technical subject matter:

U.S. Patent Application No. 10/567,381 inventors Lee *et al.*, cited herein as document **NPL40**, which is the U.S. national stage application of International Appl. No. PCT/US2004/002702, filed January 30, 2004, published as WO 05/016955 A2, cited as document **FP16** on the Information Disclosure Statement filed herewith.

U.S. Patent Application No. 11/055,163 inventors Lee *et al.*, filed February 10, 2005, cited herein as document **NPL41**, and published as U.S. Publ. No. 2005/0271655, cited herein as document **US32**.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication

Atty. Dkt. No. 2159.0450001/EJH/SAC

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SLW/

- 3 -

Relton *et al.*  
Appl. No. 10/587,714  
(*National Phase of PCT/US2005/002535*)

dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed within three months of the date of filing. No statement or fee is required.

It is respectfully requested that the Examiner initial and return copies of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

Atty. Dkt. No. 2159.0450001/EJH/SAC

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SLW/


- 4 -

Relton *et al.*  
Appl. No. 10/587,714  
(National Phase of PCT/US2005/002535)

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

*for*  #42613  
Shannon A. Carroll, Ph.D.  
Attorney for Applicants  
Registration No. 58,240

Date:

Sept 12, 2006  
1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600

580295\_1.DOC

Atty. Dkt. No. 2159.0450001/EJH/SAC

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SLW/

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SLW/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/587,714
				Filing Date	January 28, 2005
				First Named Inventor	Jane K. Relton
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	1	of	1	Attorney Docket Number	2159.0450001/EJH/SAC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	NPL37	Fuxe, K. and Ungerstedt, U., "Antiparkinsonian Drugs and Doaminergic Neostriatal Mechanisms: Studies in Rats with Unilateral 6-hydroxydopamine (=6-OH-DA)-Induced Degeneration of the Nigro-Neostriatal DA Pathway and Quantitative Recording of Rotational Behaviour," <i>Pharmacol. Ther. [B]</i> 2:41-47, Pergamon Press (1976)	
	NPL38	Gill, S.S., <i>et al.</i> , "Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease," <i>Nat. Med.</i> 9:589-595, 479, Nature Publishing Group (published online March 2003)	
	NPL39	Copy of International Preliminary Report on Patentability for International Patent Application No. PCT/US2005/002535, mailed May 12, 2006, European Patent Office, DE	
	NPL40	U.S. Patent Application No. 10/567,381, Lee <i>et al.</i> , which is the U.S. national stage application of International Appl. No. PCT/US2004/002702, filed January 30, 2004.	
	NPL41	U.S. Patent Application No. 11/055,163, Lee <i>et al.</i> , filed February 10, 2005 (published as U.S. Publ. No. 2005/0271655 A1, cited herein as document US32).	

580663v1

Examiner Signature	/Sandra Wegert/	Date Considered	09/14/2009
--------------------	-----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SLW/